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Summary During a 15-month period, we used in vivo bromodeoxyuridine (BUDR) infusion to study cell
kinetics in 112 consecutive patients with various types of malignant tumours: acute leukaemia (50 patients),
gastric cancer (42) and brain gliomas (20). The in vivo BUDR method requires that a single tumour sample be
taken 4-6h after infusion and that bivariate flow cytometry (FCM) be employed to measure simultaneously
the percentage of BUDR-labelled cells (which are identified with a green fluorescent anti-BUDR monoclonal
antibody) and their mean DNA content (following propidium iodide staining). This technique rapidly
furnishes the labelling index (LI) and the DNA synthesis time (TS), from which the tumour potential
doubling time (Tpot) and production rate (fractional turnover rate, FTR) are calculated. The procedure took
6-9h to complete and there was no immediate toxicity from BUDR administration. Successful LI and TS
determinations were obtained in 89 (80%) and 80 (72%) of the 112 patients, respectively. Correlations were
sought between kinetic parameters and a number of pathological and clinical ones. In 34 patients with acute
non-lymphoblastic leukaemias who were uniformly treated for remission (CR) induction and maintenance,
proliferative activity, as measured by Tpot and FTR, was greater in responsive than in non-responsive
patients, and in those who experienced CR for over 8 months than in those who had a shorter CR.
Proliferative activity was also greater in patients with advanced gastric cancers than in those with more
limited disease. No correlations between kinetic and clinical and pathological parameters were found in
gliomas. These data indicate the in vivo BUDR infusion coupled with FCM measurements can be performed
in clinical settings to obtain kinetic data rapidly in quite large patient series. This will probably allow the
inclusion of kinetic data in clinical trials aimed at evaluating the prognostic relevance of these data.
Since the mid 1960s investigators have been attracted by the
possibility that cell kinetics could be a parameter for cancer
prognosis and chemotherapy planning. For example, rapidly
growing tumours are expected to run a more rapid course
without treatment, but to be more sensitive to cell cycle-
dependent agents than slowly growing ones.
Gross differences in proliferative activity are known to
exist among various human tumours (Bauer et al., 1986;
Hoshino et al., 1986a; Montecucco et al., 1983; Riccardi et
al., 1986a; Silvestrini et al., 1977, 1985). For example, high
malignancy non-Hodgkin's lymphomas usually proliferate
more rapidly than acute leukaemias (AL) and multiple
myeloma. Unfortunately, substantial overlap occurs, and the
kinetic characteristics are largely unpredictable in the
individual patient.
Greater insight into this topic has been sharply limited by
the fact that the direct measurement of cell kinetics is not
easy in clinical settings. Evaluating the simplest proliferative
parameter, i.e. the S phase size, traditionally requires
tritiated thymidine (3H-TdR) cytoautoradiography (to obtain
the 3H-TdR labelling index, LI), or DNA flow
cytofluorometry (FCM) (for the percentage of cells with
DNA content intermediate between the diploid, 2n, and the
tetraploid, 4n, values: 2n-4n cell %). However,
cytoautoradiography is time consuming and, with FCM, the
S phase is not evaluable when the tumour is aneuploid, or it
is overestimated when S-phase arrested cells (U-cells)
(Riccardi et al., 1977; De Fazio et al., 1987) are present.
Furthermore, S-phase size alone gives only a partial picture
of tumour kinetics, for which a wider experimental panel of
kinetic parameters, including the duration of the cell cycle
and of its phases, is necessary. Methods for obtaining these
temporal data are exceedingly difficult to apply in humans
(Steel, 1977).
The in vivo administration of bromodeoxyuridine (BUDR,
a non-radioactive pyrimidine analogue which is incorporated
into S-phase cells) coupled with bivariate FCM for
measurements (Wilson et al., 1985) allows a complete kinetic
picture of human cancer to be obtained easily, using a single
tumour sample taken 6h after BUDR infusion and double
stained with a green fluorescent anti-BUDR monoclonal
antibody and a red fluorescent DNA dye (Begg et al., 1985;
Danova et al., 1987a; Riccardi et al., 1988). During this 6h
interval the BUDR-labelled S phase cells (the percentage of
which over the whole cell population is the LI) progress
through the cell cycle toward G2 at a rate that is inversely
related to the DNA synthesis time (TS), and that can be
measured from their mean DNA content. From LI and TS
other cell kinetic parameters such as the tumour potential
doubling time and production rate are then mathematically
derived.
We report here the kinetic data with some clinical
correlations, obtained with this method in 112 consecutive
patients with acute leukaemia (AL), malignant gastric and
brain tumours.
Materials and methods
From September 1986 to January 1988, 112 consecutive
patients with acute leukaemia (AL), malignant gastric
and brain tumours received in vivo BUDR infusion for
kinetic studies before cell specimens were obtained for
diagnostic purposes, including cytological and histological
examination. Administration of BUDR was authorised by
the Ethical Committee at the Department of Internal
Medicine of the University of Pavia, and written informed
consent was obtained from each patient.
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Cell kinetics
In vivo BUDR administration
Patients were given a 15-20min infusion of BUDR, 500mg
in 100ml sodium chloride, prepared by the Department of
Pharmacology, IRCCS Policlinico San Matteo. All tumours
were sampled 4-6h after completion of the BUDR infusion.
Two-ml BM samples were obtained by sternal aspiration in
patients with leukaemias and in 10 solid tumour patients
with normal BM cytology and histology (these are referred
to as normal BM in Table I). Two to 4mm diameter tumour
samples were obtained during surgery in patients with gastric
and brain tumours. Histologically normal gastric mucosa
was obtained from seven patients with gastric cancers
(Table II).
Sample processing
The complete procedure for obtaining single cell suspensions
for FCM from tissue samples has been detailed elsewhere
(Riccardi et al., 1988). Briefly, the cells from BM aspirates
were layered (in a ratio of 1:1) on Ficoll-Hypaque and
collected after centrifugation (6.Og for 30min). The brain
tumour specimens were dissociated by a purely mechanical
method after removal of the blood and the electrocoagulated
portions. Each sample was carefully minced with a sharp
blade and syringed through decreasing gauge needles. The
gastric tumour specimens were dissociated by incubation at
37°C in Hank's BSS (without Ca2 + or Mg2+) containing
0.2% collagenase, with slow stirring for 20-60min.
Cell suspensions from both haematological and solid
tumours were washed twice in PBS, filtered through a 35pm
pore nylon filter and resuspended in PBS. After counting
in a Biirker's chamber, they were ultimately fixed in 70%
ethanol at a concentration not exceeding 1 x 106 cellsml-1.
BUDR and DNA staining and bivariate flow cytometry
BUDR detection (Wilson et al., 1985; Danova et al., 1987b)
basically involves double stranded DNA denaturation with
2NHCl, allowing the anti-BUDR MoAb to react with
BUDR in the DNA chain (Gratzner, 1982; Moran et al.,
1985), which is then visualised by means of a standard
immunofluorescence technique. Briefly, cell suspensions were
first incubated with 2NHCl (for 30min at 37°C) and about
1 x 106 of these cells were later suspended in 1 ml of PBS
containing 0.5% Tween-20 and 0.5% normal goat serum
(NGS) for 15min at 37°C, washed in PBS, and then
incubated in 0.5ml of PBS containing Tween-20 and NGS
and IOpl of the anti-BRDU MoAb (Becton Dickinson, Lab
Impex Ltd, Twickenham, Middlesex, UK) for 30min at
room temperature with occasional mixing. Following two
washings in PBS, the cells were resuspended in 1 ml of PBS
containing Tween-20 and NGS for 15min, and later with the
second antibody (10p1 of goat anti-mouse IgG FITC
conjugate, Sigma Chemicals), in 0.5ml of PBS/Tween-20/
NGS for 30min.
For DNA staining, these cells were further washed two
times in PBS and resuspended in 4ml PBS containing
10pgml - propidium iodide (PI) (which stochiometrically
stains DNA) for 15min.
Bivariate distributions of BUDR labelling (green) versus
DNA content (red) were measured using an Ortho System
50-M Cytofluorograph (Ortho Instruments, Westwood, MA,
USA) (Wilson et al., 1985), and the data, collected in the list
mode, were analysed using an Ortho 2150 computer. An
appropriate window was used to eliminate debris, cell
doublets, triplets, etc., from the analysis. The window was
chosen by gating the cytogram of the distributions of DNA
values versus cell area. For each specimen 20,000-50,000
cells were analysed.
DNA histograms were constructed with the same
instrumentation. Normal BM and normal gastric mucosa
and brain cells (obtained at surgery for head injuries) were
used as diploid reference standard, for AL and gastric and
brain cancers, respectively. Aneuploidy was estimated from
the DNA index, i.e. the ratio between the modal channel of
the GO/I peak of the tumour population and the modal
channel of the GO/I peak of the reference standard. In cases
with unimodal DNA distribution, the percentages of cells
with 2n (GO/I phase), 4n (G2 and mitotic phases) and 2n-
4n (S phase) DNA content were determined as previously
described (Wilson et al., 1985).
Evaluation of BUDR-LI and TS
Both the LI and TS were assessed on cell samples taken 4-
6h after completion of the 1 h BUDR infusion. This
procedure (Begg et al., 1985) basically involves the
assumption that at the time of BUDR infusion the mean
DNA content of BUDR-labelled S-phase cells is in the
middle of the interval between the 2n (GO/1) and 4n (G2)
peaks (Figure la) and that the rate of cell progression
through the S phase is constant.
At the time of tumour sampling, i.e. 4-6 h later, the S
phase cells (which were labelled with BUDR at the time of
its infusion) have moved toward G2 at a rate that is
dependent on their TS. On the 4-6h cytogram their peak
DNA content distribution appears as shifted toward 4n, and
some cells have recycled to GO/I following mitosis, in that
they are found as labelled cells with 2n DNA content (Figure
1b).
From these 4-6h cytograms the LI value is established as
the percentage, over the whole population, of the S phase
cells plus half the percentage of the 2n BUDR-labelled cells.
The TS is calculated by measuring the position of the
BUDR-labelled S phase cells from their mean DNA content.
This measure allows one to determine the rate at which they
have progressed though the S phase in the interval between
BUDR infusion and tumour sampling. All S phase cells are
expected to have reached G2 at a time corresponding to TS,
which can be calculated from this progression rate.
Calculated cell kinetic parameters
Once the LI and TS were experimentally obtained from
BUDR incorporation analysis, two additional kinetic
parameters were calculated, namely the potential doubling
time (Tpot) and the cell production rate (FTR).
For these calculations a steady state condition (Steel,
1977) was arbitrarily assumed. The Tpot is hence calculated
by the formula:
Tpot(days) =[(TS/LI) x 100]/24
The reciprocal is the FTR:
FTR(cells/100 cells/day) =(LI/TS) x24
Clinical and pathological data
Thirty-four of the 50 patients with AL had untreated acute
non-lymphoblastic leukaemia (AnLL) (median age: 51 years,
range: 16-78 years; male/female, 19/15; FAB subtypes: Ml, 5
patients; M2, 6 patients; M3, 5 patients; M4, 11 patients;
M5, 5 patients; M6, 1 patient; M7: 1 patient; DNA ploidy:
diploid, 28 patients; aneuploid, 6 patients) and were
uniformly treated with a standard protocol which included
remission (CR) induction with two or three courses of
sequential vincristine, arabinosylcytosine and adriamycin and
maintenance treatment with monthly courses of different
cytostatics. The remaining 16 patients had untreated acute
lymphoblastic leukemia (ALL, 10 patients) or relapsing
AnLL (6 patients) and were treated according to different
protocols.
The 42 patients with gastric cancers (median age: 65 years,
range: 56-87 years; male/female, 26/16; Lauren histological
grading: G2, 8 patients, G3, 10 patients, Gx, 24 patients;
TNM clinical grading: II, 7 patients; III, 13 patients; IV, 22
patients; DNA ploidy: diploid, 31 patients; aneuploid, 11
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patients) underwent radical (20 patients) or palliative (22
patients) surgery.
After surgery the 20 patients with brain cancers (median
age: 55.8 years, range: 51-65 years; male/female: 13/7;
histology: glioblastoma, 9 patients; anaplastic astrocytoma,
11 patients; DNA ploidy: diploid, 9 patients; aneuploid, 11
patients) received radiation therapy (45 Gy whole brain plus
15Gy on tumour bed) and at least two courses of BCNU (or
CCNU) chemotherapy.
For all patients median follow-up is now 12 months.
Evaluation of data and statistical analysis
Fisher's exact test was employed to evaluate the differences
in clinical and pathological parameters that depended on
kinetic parameters. Differences in the duration of response
and survival in AL were analysed using the method of
Berkson & Gage (1950).
Results
The results obtained are summarised in Figure 1 and in
Tables I and II. No immediate toxicity was seen following
BUDR infusion.
Cell kinetics
To obtain the LI and TS values, the complete in vivo BUDR
procedure takes 8-9h from the start of BUDR infusion and
2-3h from the tumour sampling.
The cytogram of Figure lb is representative of the BUDR
and DNA distribution in a tumour specimen taken for both
LI and TS determinations 6h following BUDR infusion.
With respect to the cytogram of Figure la (from a tumour
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Figure 1 Bivariate distribution of bromodeoxyuridine (BUDR)
incorporation and DNA values. In (a) measurements were
performed 1 h following BUDR infusion, and all S phase
BUDR-labelled cells are in the middle (0.5) of the interval
between Gl and G2; in (b), determinations were performed 6h
following BUDR infusion. With respect to the cytogram of (a)
BUDR-labelled cells have moved through the S phase (their
mean distribution is shifted toward G2), and some of them have
already recycled (showing a diploid DNA content). For
calculating the TS, it is assumed that the rate of progression of
cells through the S phase is constant. At the time of tumour
sampling (t), the new position of the S-phase cells is measured
from their mean DNA content, and their relative movement
(RM) at this time is calculated according to the formula:
RM=FS-FG1/FG2-FGI, where F is the mean DNA red
fluorescence of the corresponding phase of the cell cycle. All S-
phase cells are expected to have reached G2 at a time
corresponding to TS. The TS is hence calculated with the
formula: TS=(0.5/RM-0.5) x t.
Table I Kinetic characteristics (determined with in vivo administration of bromodeoxyuridine) of patients with acute
non-lymphoblastic leukaemia (AnLL) according to clinical outcome
Patients No. LI P TS P Tpot P FTR P
Normal BM 10 15.4 13.7 3.6 27.3
(12.4-25.4) (11.8-21.4) (3.3-4.0) (23.2-28.5)
All AL patients 50 6.1 12.7 8.8 14.9
(0.9-11.7) (6.9-27.8) (2.8-16.7) (3.9-30)
Responsive AnLL 20 6.4 10.2 5.7 17.1
<0.06 <0.05 0.07 0.08
Non-responsive
AnLL 14 7.8 12.5 7.5 15.9
CR<8 months 8 5.4 10.0 6.8 14.6
<0.02 0.3 <0.05 0.07
CR>8 months 12 10.9 10.5 5.3 18.7
Kinetic data on histologically normal bone marrow (BM) from patients with solid tumours are shown for
comparison: LI =labelling index; TS=DNA synthesis time, hours; Tpot=potential doubling time, days;
FTR=production rate cells per 100 cells per day; to calculate Tpot and FTR from the experimentally determined LI
and TS, a steady state model for cell proliferation was assumed.
Table II Kinetic characteristics (determined with in vivo administration of
bromodeoxyuridine) of patients with gastric cancers according to extent of the disease at
diagnosis
Patients No. LI P TS P Tpot P FTR P
Normal
Gastric mucosa 7 5.9 10.9 6.8 12.5
0.01 0.02 n.s. 0.05
Gastric cancers 21 10.7 14.4 8.4 14.1
Stage 11+III 10 8.9 14.5 6.7 15.8
0.02 n.s. <0.05 <0.03
Stage IV 11 13.3 13.5 4.9 23.2
Kinetic data on histologically normal gastric mucosa from patients with gastric
tumours are shown for comparison (abbreviations as in Table I).
-40IN VIVO BUDR ADMINISTRATION 901
sample taken immediately after BUDR infusion), the
position of the BUDR-labelled cells is shifted to the right. In
the 6h interval between BUDR infusion and tumour
sampling, cells have in fact moved through S phase and
some have already recycled (they appear with a diploid
DNA content in the cytogram).
The LI was successfully determined on all normal BM and
gastric mucosa samples and in 89 of 112 (80%) tumour
samples from patients who received BUDR infusion (46/50
patients with AL, 27/42 patients with gastric cancers and 16/
20 patients with brain gliomas). The TS could be derived for
all normal BM and gastric mucosa samples and in 80 of 112
(72%) tumour samples (44/50 patients with AL, 21/42
patients with gastric cancers and 15/20 patients with brain
gliomas), all of whom also had successful LI measurement.
Reasons for failure, in decreasing order, were: the lack of
sufficient cells for FCM (due to insufficient material
obtained), the presence of few viable cells in the biopsy (due
to histologically proven necrosis), and the difficulty of
obtaining clean single-cell suspensions.
Correlations between kinetic and pathological data
Tables I and II summarise what kinetic differences were
found in accordance with the above mentioned pathological
and clinical patient characteristics. Obviously, the kinetic
data concern only patients who had successful determination
of both LI and TS.
The 20 responsive AnLL patients had a shorter Tpot and
greater FTR than the 14 non-responsive ones, due to a
significantly shorter TS (Table I). Responsive patients who
experienced CR>8 months had proliferative activity higher
than those with shorter CR, mainly due to higher LI values.
Proliferative activity was greater in 11 patients with
advanced gastric cancers than in 10 with more limited
disease, and this was mainly accounted for by differences in
LI. No differences in proliferative activity were found to be
dependent on histology and DNA ploidy, and no
correlations were found between proliferative activity and
local or distant tumour recurrence and patient survival.
In malignant brain tumours median values for LI, TS,
Tpot and FTR were, respectively, 6.4 (range: 3.1-10.1)%,
14.8 (9.8-22.7)h, 12.1 (6.0-26.8) days and 9.7 (3.7-16.4) cells
per 100 cells per day. No differences in clinical behaviour
were found depending on any of the above mentioned
parameters.
Discussion
In this study, administering BUDR to patients and
employing bivariate FCM to measure simultaneously BUDR
incorporation and DNA content has allowed a complete
panel of kinetic parameters to be obtained for several human
tumours in a short time, while using only one tumour
sample. This indicates that this method can be used to
evaluate the proliferative behaviour of neoplasias in clinical
settings. Some correlations between kinetic and clinical data
were also obtained.
In a preceding paper (Riccardi et al., 1988) we thoroughly
discussed the advantages of using the in vivo BUDR method
for studying cell kinetics in a variety of human tumours, and
will briefly summarise them here. The first reason favouring
this over the traditional cytokinetic methods is that it
furnishes an S phase evaluation which is easier and more
accurate than that obtained from both 3H-TdR
cytoautoradiography and DNA FCM. With respect to 3H-
TdR cytoautoradiography the in vivo BUDR procedure is
more rapidly accomplished and a much greater number of
cells is evaluated. With respect to DNA FCM, an accurate
estimation of the S phase can be obtained in both aneuploid
tumours (no mathematical model allows this from the simple
DNA histogram) and in tumours where a number of 2n-4n
BUDR unlabelled cells (U-cells) (Riccardi et al., 1977; De
Fazio et al., 1987) exist. A second advantage of the in vivo
BUDR method is that it also furnishes the rate at which
proliferating cells synthesise DNA, i.e. the TS, a parameter
which is exceedingly difficult to obtain with the traditional
techniques (Steel, 1977). With in vivo BUDR the TS is
simply evaluated from measuring the degree of the
progression rate toward G2 of the BUDR-labelled cells in
the interval (4-6h) between BUDR infusion and tumour
sampling (Figure 1), assuming that cell progression through
the S phase is constant (Begg et al., 1985). The TS values we
obtained were strictly related to those drawn, on duplicate
samples, from quantitative 14C-TdR cytoautoradiography
(Riccardi et al., 1988), which is an accepted method for
calculating TS. From the experimentally obtained LI and
TS, a number of temporal kinetic parameters can be
calculated (Dormer, 1973; Steel, 1977; Ucci et al., 1985),
assuming either a steady state or other more complex models
for cell proliferation (Steel, 1977). We calculated the Tpot,
i.e. the time in which the whole tumour duplicates, and the
FTR, i.e. its rate of cell production, as the most meaningful
for giving an overall picture of tumour growth.
The major advantage of the in vivo BUDR procedure is,
however, that it is feasible in clinical settings. There are no
reports of immediate adverse reactions following BUDR
infusion; only one tumour sample is required for the study,
and this is needed anyway for diagnostic or therapeutic
purposes. The whole procedure takes 8-9h from the start of
BUDR infusion and only 2-3h from the tumour sampling.
In this way we were able to investigate quite a large number
of consecutive patients in a 15-month period, obtaining
accurate LI values in over two-thirds of the cases and TS,
Tpot and FTR values in over half (Riccardi et al., 1988).
There are other rapidly progressing clinical studies with in
vivo BUDR which employ FCM or immunohistochemistry
for detecting the BUDR-labelled cells. They include very
large series of AL and chronic myelogenous leukaemia (Raza
et al., 1987), malignant and benign brain tumours (Cho et
al., 1986; Hoshino et al., 1985, 1986a,b Danova et al.,
1988a; Murovic et al., 1986; Nagashima et al., 1986), gastric
(Dionigi et al., 1988; Danova et al., 1988b) and ovarian
cancers (Erba & Mangioni, unpublished data) as well as
miscellaneous tumours (Riccardi et al., 1988; Wilson et al.,
1989). For solid neoplasias a long-discussed possibility is
that kinetic parameters change in different areas of the
tumour, so that the proliferative characteristics obtained may
not be representative of overall tumour kinetics.. In vivo
BUDR incorporation analysis has permitted us to begin
investigating this point. We examined six patients with
gastric tumours who had had LI and TS measured on two
different tumour samples, and the intratumoral kinetic
variation was not great (Riccardi et al., 1988).
In the present study a preliminary attempt was made to
correlate kinetic with clinical data in cases who had both LI
and TS determinations. In 34 uniformly treated AnLL
patients proliferative activity, as measured from Tpot and
FTR, was greater in responsive than in non-responsive cases
and in those who experienced CR for over 8 months than in
those who had a shorter CR, suggesting that high
proliferative activity is a favourable prognostic factor in this
disease. We believe that these data on AL are of true clinical
relevance. For many years investigators have tried to
evaluate the clinical interest of proliferative activity in
previously untreated AL by evaluating the S phase with 3H-
TdR cytoautoradiography or DNA FCM. A number of
them reported that CR was more frequent with high S phase
values; others failed to confirm this finding but none
reported an advantage with low S phase values (Riccardi et
al., 1986a). In this series LI was not different in responsive
and non-responsive patients, but the responsive ones had a
shorter Tpot and greater FTR due to a shorter TS. A
response advantage for AL patients with shorter TS was also
reported using the 3H- and 14C-TdR double labelling tech-
nique (Paietta et al., 1980) or in vivo BUDR coupled with im-902 A. RICCARDI et al.
munohistochemistry (Raza et al., 1985, 1987). From these
data the concept that a high proliferative activity favours
CR in AnLL, due to a high S phase value and/or a short
TS, can be accepted. Of course, the prognostic significance
of proliferative activity must be better ascertained from the
multivariate analysis of other clinical and laboratory
features. The in vivo BUDR method allows one to include
kinetic behaviour in this analysis.
No literature reports exist on the in vivo kinetic
characteristics of gastric cancers. The distinctly greater
proliferative activity in advanced (stage IV) disease could
suggest that high proliferative activity favours tumour
progression. Correlations with treatment results were not
expected since our series is too small to account for the large
number (histology, DNA ploidy, clinical stage at diagnosis,
palliative or radical surgery, local or distant tumour recur-
rence) influencing treatment outcome in this disease.
We conclude that the cell kinetics of human tumours can
be reliably studied in clinical settings by combining in vivo
BUDR administration and FCM measurements of BUDR
incorporation and DNA content. In prospective
investigations the prognostic meaning of proliferative activity
and its usefulness in planning antitumour treatments can be
ascertained.
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